ReviewNaunyn-Schmiedeberg's archives of pharmacology2026
Beyond LDL-C reduction: molecular pleiotropy and emerging therapeutic roles of statins.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Statins rank among the most prevalent pharmacological treatments for the prevention and management of atherosclerotic cardiovascular disease, chiefly by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase and consequently reducing low-density lipoprotein cholesterol (LDL-C) levels. In addition to their recognized lipid-lowering properties, experimental, translational, and clinical research has uncovered various possible pleiotropic effects. These cholesterol-independent effects relate to the modulation of the mevalonate pathway and subsequent signaling molecules, which may affect endothelial function, nitric oxide availability, oxidative stress, inflammatory responses, atherosclerotic plaque stability, and thrombotic mechanisms. Nonetheless, the degree to which these processes yield clinically significant advantages apart from LDL-C lowering is still ambiguous. The clinical pharmacology of statins is examined, encompassing their pharmacokinetic and pharmacodynamic characteristics, molecular mechanisms of action, and novel therapeutic applications. Particular attention is directed at the molecular foundation and clinical relevance of statin pleiotropy in neurological conditions, metabolic disorders, inflammatory and autoimmune diseases, infectious illnesses, and cancer. The advantages and drawbacks of these prospective indications are rigorously assessed utilizing data from preclinical investigations, observational studies, randomized controlled trials, and meta-analyses. The evaluation additionally discusses safety factors, clinically significant drug-drug interactions, and the influence of pharmacogenomics in formulating individualized treatment approaches. Overall, statins have well-established cardiovascular benefits, whereas the clinical significance of their proposed pleiotropic effects and potential applications beyond cardiovascular disease varies across indications and remains incompletely established. Further high-quality, indication-specific clinical trials are needed to determine whether these effects provide additional therapeutic benefits and to define their appropriate clinical roles.
Indexed as
Identifiers
42961645What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.